EVELYN KELLEY: Open Payments
NPI 1710569694 · MENIFEE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$948 in 49 payments from 16 companies in 2025. Trend: 2023 $430 · 2024 $723 · 2025 $948
Food & beverage: $948
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $202 |
| Otsuka America Pharmaceutical, Inc. | 5 | $114 |
| Novo Nordisk Inc | 4 | $91 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $87 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| Lilly USA, LLC | 4 | $79 |
| Lundbeck LLC | 4 | $63 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Exact Sciences Corporation | 2 | $36 |
| Astellas Pharma US Inc | 1 | $34 |
Products named: REXULTI, AIRSUPRA, JARDIANCE, Wegovy, SHINGRIX, MOUNJARO, BREZTRI, GVOKE HYPOPEN.
Industry payments across CA — which companies pay providers there.
